JP7454320B2 - アジュバントとしての腫瘍溶解性ウイルス - Google Patents
アジュバントとしての腫瘍溶解性ウイルス Download PDFInfo
- Publication number
- JP7454320B2 JP7454320B2 JP2020544653A JP2020544653A JP7454320B2 JP 7454320 B2 JP7454320 B2 JP 7454320B2 JP 2020544653 A JP2020544653 A JP 2020544653A JP 2020544653 A JP2020544653 A JP 2020544653A JP 7454320 B2 JP7454320 B2 JP 7454320B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- prime
- boost
- antigenic protein
- mrb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000309459 oncolytic virus Species 0.000 title claims description 59
- 239000002671 adjuvant Substances 0.000 title description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 196
- 230000000890 antigenic effect Effects 0.000 claims description 195
- 102000004169 proteins and genes Human genes 0.000 claims description 195
- 206010028980 Neoplasm Diseases 0.000 claims description 131
- 230000028993 immune response Effects 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000000427 antigen Substances 0.000 claims description 71
- 241000124008 Mammalia Species 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 30
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241000700605 Viruses Species 0.000 description 192
- 108090000765 processed proteins & peptides Proteins 0.000 description 140
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 73
- 150000001413 amino acids Chemical class 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 51
- 102000004196 processed proteins & peptides Human genes 0.000 description 49
- 238000011260 co-administration Methods 0.000 description 32
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 29
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 28
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 28
- 210000004988 splenocyte Anatomy 0.000 description 27
- 230000002238 attenuated effect Effects 0.000 description 26
- 241000711975 Vesicular stomatitis virus Species 0.000 description 25
- 238000001990 intravenous administration Methods 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 241000701161 unidentified adenovirus Species 0.000 description 24
- 238000007918 intramuscular administration Methods 0.000 description 23
- 230000004083 survival effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 108091006027 G proteins Proteins 0.000 description 19
- 102000030782 GTP binding Human genes 0.000 description 19
- 108091000058 GTP-Binding Proteins 0.000 description 19
- 101710085938 Matrix protein Proteins 0.000 description 19
- 101710127721 Membrane protein Proteins 0.000 description 19
- 238000000692 Student's t-test Methods 0.000 description 19
- 241000700618 Vaccinia virus Species 0.000 description 19
- 238000012353 t test Methods 0.000 description 19
- 241001372913 Maraba virus Species 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 241000712079 Measles morbillivirus Species 0.000 description 12
- 230000002601 intratumoral effect Effects 0.000 description 11
- 230000037452 priming Effects 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 230000000174 oncolytic effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000172083 Gray Lodge virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229940038426 oncolytic vaccine Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 241001428876 Adelaide River virus Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001330999 Almpiwar virus Species 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000172103 Aruac virus Species 0.000 description 1
- 241000255797 Bahia Grande virus Species 0.000 description 1
- 241001674104 Bangoran virus Species 0.000 description 1
- 241000479165 Barur virus Species 0.000 description 1
- 241000172078 BeAn 157575 virus Species 0.000 description 1
- 241001331006 Berrimah virus Species 0.000 description 1
- 241001674102 Bimbo virus Species 0.000 description 1
- 241000897511 Bivens Arm virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001674094 Boteke virus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000219076 Calchaqui virus Species 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- 241000702749 Carajas virus Species 0.000 description 1
- 241001435774 Chaco virus Species 0.000 description 1
- 241000711969 Chandipura virus Species 0.000 description 1
- 241001331000 Charleville virus Species 0.000 description 1
- 241000296422 Coastal Plains virus Species 0.000 description 1
- 241000501789 Cocal virus Species 0.000 description 1
- 241000172104 Connecticut virus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000172082 DakArK 7292 virus Species 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 241001460770 Eel virus American Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241001470863 Flanders hapavirus Species 0.000 description 1
- 241001331001 Fukuoka virus Species 0.000 description 1
- 241001674098 Garba virus Species 0.000 description 1
- 241001518816 Gossas virus Species 0.000 description 1
- 241001144654 Hart Park virus Species 0.000 description 1
- 241000276608 Herichthys cyanoguttatus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 241001330996 Humpty doo virus Species 0.000 description 1
- 241001109688 Isfahan virus Species 0.000 description 1
- 241000172090 Joinjakaka virus Species 0.000 description 1
- 241001481498 Jurona vesiculovirus Species 0.000 description 1
- 241001144663 Kamese virus Species 0.000 description 1
- 241000172091 Kannamangalam virus Species 0.000 description 1
- 241000479164 Kern Canyon virus Species 0.000 description 1
- 241000479170 Keuraliba virus Species 0.000 description 1
- 241001331013 Kimberley virus Species 0.000 description 1
- 241000897510 Klamath virus Species 0.000 description 1
- 241000479166 Kolongo virus Species 0.000 description 1
- 241000182270 Koolpinyah virus Species 0.000 description 1
- 241000479160 Kotonkon virus Species 0.000 description 1
- 241000172088 Kwatta virus Species 0.000 description 1
- 241000172089 La Joya virus Species 0.000 description 1
- 241000172086 Landjia virus Species 0.000 description 1
- 241001331002 Le Dantec virus Species 0.000 description 1
- 241001481497 Malpais Spring vesiculovirus Species 0.000 description 1
- 241000172085 Manitoba virus Species 0.000 description 1
- 241001435771 Marco virus Species 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001144665 Mosqueiro virus Species 0.000 description 1
- 241001144667 Mossuril virus Species 0.000 description 1
- 241000256205 Muir Springs virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101710197954 N-(5-amino-5-carboxypentanoyl)-L-cysteinyl-D-valine synthase Proteins 0.000 description 1
- 241001674100 Nasoule virus Species 0.000 description 1
- 241000172094 Navarro virus Species 0.000 description 1
- 241001471094 Ngaingan hapavirus Species 0.000 description 1
- 241000479169 Nkolbisson virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001331020 Oak-Vale virus Species 0.000 description 1
- 241000468053 Obodhiang virus Species 0.000 description 1
- 241000172093 Oita virus Species 0.000 description 1
- 241001674105 Ouango virus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001330997 Parry Creek virus Species 0.000 description 1
- 241001481499 Perinet vesiculovirus Species 0.000 description 1
- 241000711965 Piry virus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000479163 Sandjimba virus Species 0.000 description 1
- 241000489194 Sawgrass virus Species 0.000 description 1
- 241000172098 Sena Madureira virus Species 0.000 description 1
- 240000004672 Sigmavirus Species 0.000 description 1
- 241000489196 Sripur virus Species 0.000 description 1
- 241000172096 Sweetwater Branch virus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 241001330998 Tibrogargan virus Species 0.000 description 1
- 241001435769 Timbo virus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241001329715 Tupaia virus Species 0.000 description 1
- 241001517166 Vesicular stomatitis Alagoas virus Species 0.000 description 1
- 241000172097 Xiburema virus Species 0.000 description 1
- 241000172105 Yata virus Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000054725 human STEAP1 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- CWEFIMQKSZFZNY-UHFFFAOYSA-N pentyl 2-[4-[[4-[4-[[4-[[4-(pentoxycarbonylamino)phenyl]methyl]phenyl]carbamoyloxy]butoxycarbonylamino]phenyl]methyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCCCCC)=CC=C1CC(C=C1)=CC=C1NC(=O)OCCCCOC(=O)NC(C=C1)=CC=C1CC1=CC=C(NC(=O)OCCCCC)C=C1 CWEFIMQKSZFZNY-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims (2)
- a.腫瘍溶解性ウイルス及び哺乳動物において免疫応答を生じさせることができる少なくとも1つの抗原タンパク質を含むプライム組成物;及び
b.哺乳動物において免疫応答を誘導するように製剤化された、腫瘍溶解性ウイルス及び少なくとも1つの抗原タンパク質を含むブースト組成物
を含むプライム:ブーストワクチンであって、
前記プライム組成物の前記少なくとも1つの抗原タンパク質及び前記ブースト組成物の前記少なくとも1つの抗原タンパク質が同じ腫瘍抗原由来であり、
前記プライム組成物の前記少なくとも1つの抗原タンパク質が前記プライム組成物の前記腫瘍溶解性ウイルスによってコードされておらず、
前記ブースト組成物の前記少なくとも1つの抗原タンパク質が前記ブースト組成物の前記腫瘍溶解性ウイルスによってコードされておらず、
前記プライム組成物の前記腫瘍溶解性ウイルスは前記ブースト組成物の前記腫瘍溶解性ウイルスとは免疫学的に異なる、
プライム:ブーストワクチン。 - a.腫瘍溶解性ウイルス及び哺乳動物において免疫応答を生じさせることができる少なくとも1つの抗原タンパク質を含むプライム;及び
b.哺乳動物において免疫応答を誘導するように製剤化された、腫瘍溶解性ウイルス及び少なくとも1つの抗原タンパク質を含むブースト
を含むキットであって、
前記プライムの前記少なくとも1つの抗原タンパク質及び前記ブーストの前記少なくとも1つの抗原タンパク質が同じ腫瘍抗原由来であり、
前記プライムの前記少なくとも1つの抗原タンパク質が前記プライムの前記腫瘍溶解性ウイルスによってコードされておらず、
前記ブーストの前記少なくとも1つの抗原タンパク質が前記ブーストの前記腫瘍溶解性ウイルスによってコードされておらず、
前記プライムの前記腫瘍溶解性ウイルスは前記ブーストの前記腫瘍溶解性ウイルスとは免疫学的に異なる、
キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633883P | 2018-02-22 | 2018-02-22 | |
US62/633,883 | 2018-02-22 | ||
US201862751091P | 2018-10-26 | 2018-10-26 | |
US62/751,091 | 2018-10-26 | ||
PCT/CA2019/050220 WO2019161505A1 (en) | 2018-02-22 | 2019-02-22 | Oncolytic viruses as adjuvants |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021514381A JP2021514381A (ja) | 2021-06-10 |
JPWO2019161505A5 JPWO2019161505A5 (ja) | 2022-02-24 |
JP7454320B2 true JP7454320B2 (ja) | 2024-03-22 |
Family
ID=67686712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020544653A Active JP7454320B2 (ja) | 2018-02-22 | 2019-02-22 | アジュバントとしての腫瘍溶解性ウイルス |
Country Status (6)
Country | Link |
---|---|
US (2) | US20200397892A1 (ja) |
EP (1) | EP3755369A4 (ja) |
JP (1) | JP7454320B2 (ja) |
CN (1) | CN112399855A (ja) |
CA (1) | CA3091969A1 (ja) |
WO (1) | WO2019161505A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500229A (ja) | 2008-08-21 | 2012-01-05 | オタワ ホスピタル リサーチ インスティチュート | 遺伝子操作された相乗的腫瘍溶解性ウイルス共生 |
JP2016513115A (ja) | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
KR20070104881A (ko) * | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
MX362698B (es) * | 2007-03-02 | 2019-02-01 | Glaxosmithkline Biologicals Sa | Metodo novedoso y composiciones. |
WO2010105347A1 (en) * | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
US20130122038A1 (en) * | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
NZ726112A (en) * | 2014-05-19 | 2021-07-30 | Valo Therapeutics Oy | Coated adenoviruses for immunotherapy |
WO2016025295A1 (en) * | 2014-08-06 | 2016-02-18 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
BR112018073007A2 (pt) * | 2016-05-09 | 2019-07-02 | Turnstone Lp | terapia de combinação inicial:reforço |
-
2019
- 2019-02-22 EP EP19756747.2A patent/EP3755369A4/en active Pending
- 2019-02-22 CA CA3091969A patent/CA3091969A1/en active Pending
- 2019-02-22 JP JP2020544653A patent/JP7454320B2/ja active Active
- 2019-02-22 US US16/971,285 patent/US20200397892A1/en active Pending
- 2019-02-22 WO PCT/CA2019/050220 patent/WO2019161505A1/en unknown
- 2019-02-22 CN CN201980027179.0A patent/CN112399855A/zh active Pending
-
2023
- 2023-04-26 US US18/307,593 patent/US20230285552A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500229A (ja) | 2008-08-21 | 2012-01-05 | オタワ ホスピタル リサーチ インスティチュート | 遺伝子操作された相乗的腫瘍溶解性ウイルス共生 |
JP2016513115A (ja) | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
Non-Patent Citations (2)
Title |
---|
AITKEN, A. S. et al.,Biomedicines,2017年,5(1): 3 |
EXPLOITING THE IMMUNOGENIC CANCER MUTANOME TO ENHANCE ONCOLYTIC VIRUS THERAPY [online], [retrieved on 2023.03.23],2014年,https://ruor.uottawa.ca/bitstream/10393/31409/1/Marguerie_Monique_2104_thesis.pdf,Combining the Immunogenic Cancer Mutanome with Oncolytic Virus Therapy, https://ruor.uottawa.ca/handle/10393/31409 |
Also Published As
Publication number | Publication date |
---|---|
EP3755369A1 (en) | 2020-12-30 |
CN112399855A (zh) | 2021-02-23 |
EP3755369A4 (en) | 2022-01-19 |
JP2021514381A (ja) | 2021-06-10 |
WO2019161505A1 (en) | 2019-08-29 |
CA3091969A1 (en) | 2019-08-29 |
US20230285552A1 (en) | 2023-09-14 |
US20200397892A1 (en) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10925946B2 (en) | Vaccination methods | |
ES2741147T3 (es) | Composición de vacuna | |
Rintoul et al. | ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic | |
JP2019526580A5 (ja) | ||
WO2015106697A1 (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
JP2011500718A5 (ja) | ||
EP3077408A1 (en) | Molecular adjuvant | |
JP6205012B2 (ja) | 水疱性口内炎ウイルス | |
WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
US20200246443A1 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
JP2019527737A (ja) | Il12を発現する腫瘍溶解性ラブドウイルス | |
US10849964B2 (en) | Methods and materials for treating cancer | |
Bonilla et al. | Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack | |
US20220152168A1 (en) | Sequential heterologous boost oncolytic viral immunotherapy | |
JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
US20120171246A1 (en) | Immunization to reduce neurotoxicity during treatment with cytolytic viruses | |
US9862931B2 (en) | Adenovirus vaccine vectors | |
EP2407177A1 (en) | Adenovirus vaccine vectors | |
JP2024056911A (ja) | 異種組合せプライム:ブースト療法及び処置の方法 | |
CA3132054A1 (en) | A heterologous combination prime:boost therapy and methods of treatment | |
AuYeung | Immunological effects of oncolytic virotherapy in the context of a preclinical model of melanoma | |
WO2019113703A1 (en) | Combination prime:boost therapy | |
Bonilla et al. | Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220215 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240307 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7454320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |